Asia Pacific Insulin Market Size & Outlook, 2023-2030
Asia Pacific insulin market, 2018-2030 (US$M)
Related Markets
Asia Pacific insulin market highlights
- The Asia Pacific insulin market generated a revenue of USD 5,187.2 million in 2023.
- The market is expected to grow at a CAGR of 4.6% from 2024 to 2030.
- In terms of segment, insulin analog was the largest revenue generating type in 2023.
- Insulin Analog is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 5,187.2 million |
| Market revenue in 2030 | USD 7,094.5 million |
| Growth rate | 4.6% (CAGR from 2023 to 2030) |
| Largest segment | Insulin analog |
| Fastest growing segment | Insulin Analog |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Insulin Analog, Human Insulin |
| Key market players worldwide | Novo Nordisk A/S ADR, Eli Lilly and Co, Sanofi SA, United Laboratories International Holdings Ltd, Biocon, Wockhardt, Boehringer Ingelheim Pharma, Tonghua Dongbao Pharmaceutical, Julphar |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 26.2% of the global insulin market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 7,094.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Insulin Market Scope
Insulin Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific insulin market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to insulin market will help companies and investors design strategic landscapes.
Insulin analog was the largest segment with a revenue share of 88.66% in 2023. Horizon Databook has segmented the Asia Pacific insulin market based on insulin analog, human insulin covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is expected to witness significant growth over the forecast period, owing to factors such as rising geriatric & target populations, increasing number of collaborations for development of biosimilars, geographic expansion of key players, and active participation of government & nonprofit organizations in the market space.
Furthermore, health awareness campaigns and scientific conferences for the management of this disease may fuel market growth in the region. More than 114 million people are living with diabetes in China.
With China being the most populated country in the world, improving treatment efficiency in metabolic diseases has become crucial. Increasing approval of insulin products in China is anticipated to drive market growth.
Reasons to subscribe to Asia Pacific insulin market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific insulin market databook
-
Our clientele includes a mix of insulin market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific insulin market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific insulin market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific insulin market size, by country, 2018-2030 (US$M)
Asia Pacific Insulin Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
